Vicore Pharma Holding AB is a clinical-stage pharmaceutical company headquartered in Stockholm, Sweden, specializing in treatments for rare lung diseases and scarring disorders. The company's principal focus is on unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs) to stabilize or reverse lung function decline. Its lead clinical program, buloxibutid (C21), is an orally available small molecule currently in Phase 2 development for idiopathic pulmonary fibrosis (IPF) and has received Orphan Drug and Fast Track designations from the US FDA. In addition to its traditional drug pipeline, Vicore is developing Almee, a digital therapeutic based on cognitive behavioral therapy to help patients manage the psychological burden of pulmonary fibrosis. The company operates primarily through research partnerships, clinical trials, and licensing arrangements, aiming to bring disease-modifying therapies to specialist lung-care markets globally.
The sum of declared dividends issued by a company for every ordinary share outstanding.
Dividend Yield is a financial ratio that shows how much a company pays out in dividends each year relative to its share price in the last twelve months. In the absence of any capital gains, the dividend yield is the return on investment for a stock.
It is another way that companies have to remunerate their shareholders, being an alternative to dividends. Shows the % of repurchases per share made in the last 12 months in relation to the share price.
Sum of Dividend Yield and BuyBack Yield to show the total return that the shareholder received in the last 12 months in relation to the share price.
The dividend payout ratio is the ratio of the total amount of dividends paid out to shareholders relative to the net income of the company. It is the percentage of earnings paid to shareholders via dividends.
...and much more!